These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

379 related articles for article (PubMed ID: 28238592)

  • 1. Frequency of carcinoid syndrome at neuroendocrine tumour diagnosis: a population-based study.
    Halperin DM; Shen C; Dasari A; Xu Y; Chu Y; Zhou S; Shih YT; Yao JC
    Lancet Oncol; 2017 Apr; 18(4):525-534. PubMed ID: 28238592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Octreotide long-acting repeatable use among elderly patients with carcinoid syndrome and survival outcomes: a population-based analysis.
    Shen C; Shih YC; Xu Y; Yao JC
    Cancer; 2014 Jul; 120(13):2039-49. PubMed ID: 24676892
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of carcinoid syndrome on the clinical characteristics and outcomes of patients with gastroenteropancreatic neuroendocrine tumors undergoing operative resection.
    Kimbrough CW; Beal EW; Dillhoff ME; Schmidt CR; Pawlik TM; Lopez-Aguiar AG; Poultsides G; Makris E; Rocha FG; Crown A; Abbott DE; Fisher AV; Fields RC; Krasnick BA; Idrees K; Marincola-Smith P; Cho CS; Beems M; Maithel SK; Cloyd JM
    Surgery; 2019 Mar; 165(3):657-663. PubMed ID: 30377003
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Carcinoid Syndrome and Costs of Care During the First Year After Diagnosis of Neuroendocrine Tumors Among Elderly Patients.
    Shen C; Chu Y; Halperin DM; Dasari A; Zhou S; Xu Y; Yao JC; Shih YT
    Oncologist; 2017 Dec; 22(12):1451-1462. PubMed ID: 28642335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours.
    Kostiainen I; Karppinen N; Simonen P; Rosengård-Bärlund M; Lindén R; Tarkkanen M; Gordin D; Rapola J; Schalin-Jäntti C; Matikainen N
    Endocrine; 2022 Jun; 77(1):177-187. PubMed ID: 35536452
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical benefits of above-standard dose of octreotide LAR in patients with neuroendocrine tumors for control of carcinoid syndrome symptoms: a multicenter retrospective chart review study.
    Strosberg JR; Benson AB; Huynh L; Duh MS; Goldman J; Sahai V; Rademaker AW; Kulke MH
    Oncologist; 2014 Sep; 19(9):930-6. PubMed ID: 25096997
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Management of Diarrhea in Patients With Carcinoid Syndrome.
    Naraev BG; Halland M; Halperin DM; Purvis AJ; OʼDorisio TM; Halfdanarson TR
    Pancreas; 2019 Sep; 48(8):961-972. PubMed ID: 31425482
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pazopanib and depot octreotide in advanced, well-differentiated neuroendocrine tumours: a multicentre, single-group, phase 2 study.
    Phan AT; Halperin DM; Chan JA; Fogelman DR; Hess KR; Malinowski P; Regan E; Ng CS; Yao JC; Kulke MH
    Lancet Oncol; 2015 Jun; 16(6):695-703. PubMed ID: 25956795
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive factors associated with carcinoid syndrome in patients with gastrointestinal neuroendocrine tumors.
    Cai B; Broder MS; Chang E; Yan T; Metz DC
    World J Gastroenterol; 2017 Oct; 23(40):7283-7291. PubMed ID: 29142475
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differential diagnosis of diarrhoea in patients with neuroendocrine tumours: A systematic review.
    Khan MS; Walter T; Buchanan-Hughes A; Worthington E; Keeber L; Feuilly M; Grande E
    World J Gastroenterol; 2020 Aug; 26(30):4537-4556. PubMed ID: 32874063
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Octreotide long-acting repeatable among elderly patients with neuroendocrine tumors: a survival analysis of SEER-Medicare data.
    Shen C; Shih YC; Xu Y; Yao JC
    Cancer Epidemiol Biomarkers Prev; 2015 Nov; 24(11):1656-65. PubMed ID: 26315553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumours of the midgut (jejunum, ileum and ascending colon, including carcinoid syndrome).
    de Herder WW
    Best Pract Res Clin Gastroenterol; 2005 Oct; 19(5):705-15. PubMed ID: 16253895
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost reduction from resolution/improvement of carcinoid syndrome symptoms following treatment with above-standard dose of octreotide LAR.
    Huynh L; Totev T; Vekeman F; Neary MP; Duh MS; Benson AB
    J Med Econ; 2017 Sep; 20(9):945-951. PubMed ID: 28562131
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LANREOTIDE THERAPY IN CARCINOID SYNDROME: PROSPECTIVE ANALYSIS OF PATIENT-REPORTED SYMPTOMS IN PATIENTS RESPONSIVE TO PRIOR OCTREOTIDE THERAPY AND PATIENTS NAÏVE TO SOMATOSTATIN ANALOGUE THERAPY IN THE ELECT PHASE 3 STUDY.
    Fisher GA; Wolin EM; Liyanage N; Lowenthal SP; Mirakhur B; Pommier RF; Shaheen M; Vinik AI;
    Endocr Pract; 2018 Mar; 24(3):243-255. PubMed ID: 29547049
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Neuroendocrine tumours of the GI tract--data from the German NET Registry].
    Begum N; Maasberg S; Plöckinger U; Anlauf M; Rinke A; Pöpperl G; Lehnert H; Izbicki JR; Krausch M; Vashist YK; Raffel A; Bürk CG; Hoffmann J; Goretzki P; Pape UF;
    Zentralbl Chir; 2014 Jun; 139(3):276-83. PubMed ID: 23042103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gastroenteropancreatic neuroendocrine (carcinoid) tumors in children.
    Johnson PR
    Semin Pediatr Surg; 2014 Apr; 23(2):91-5. PubMed ID: 24931354
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patient-reported outcomes with lanreotide Autogel/Depot for carcinoid syndrome: An international observational study.
    Ruszniewski P; Valle JW; Lombard-Bohas C; Cuthbertson DJ; Perros P; Holubec L; Delle Fave G; Smith D; Niccoli P; Maisonobe P; Atlan P; Caplin ME;
    Dig Liver Dis; 2016 May; 48(5):552-558. PubMed ID: 26917486
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Best prognostic factor of neuroendocrine tumors: Grade or Stage? A multidisciplinary single-center study.
    Özaslan E; Bayram F; Karaca H; Gürsoy Ş; Öztürk F; Sözüer E; Abdurrezzak Ü; Yurci A; Can Sezgin G; Yıldırım A; Başpınar O; Kula M; Özkan M
    Turk J Gastroenterol; 2016 Nov; 27(6):509-514. PubMed ID: 27852541
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Gastrointestinal carcinoids: characterization by site of origin and hormone production.
    Onaitis MW; Kirshbom PM; Hayward TZ; Quayle FJ; Feldman JM; Seigler HF; Tyler DS
    Ann Surg; 2000 Oct; 232(4):549-56. PubMed ID: 10998653
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Neuroendocrine tumors of the gallbladder: an evaluation and reassessment of management strategy.
    Eltawil KM; Gustafsson BI; Kidd M; Modlin IM
    J Clin Gastroenterol; 2010; 44(10):687-95. PubMed ID: 20375728
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.